Physician profile
Lawrence Morris
NPI 1366419558
$571.36
in general payments reported to CMS, 2019-2025
11 companies · $23.31 in 2025
The $23.31 reported for 2025 was less than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $218 · 2020: $61.79 · 2021: $18.11 · 2022: $19.84 · 2023: $171 · 2024: $59.64 · 2025: $23.31.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $254.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $253.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $233.56 | 2019-2020 | |
| Celgene Corporation | $130.73 | 2023 | Reblozyl |
| Abbvie INC. | $70.69 | 2023-2025 | |
| Amgen INC. | $34.37 | 2019-2022 | |
| Octapharma USA, INC. | $33.19 | 2023-2024 | Octagam Immune Globulin (Human), Panzyga |
| Adc Therapeutics America, INC. | $19.04 | 2024 | |
| Epizyme, INC. | $18.11 | 2021 | |
| Adaptive Biotechnologies Corporation | $16.10 | 2020 | |
| Seagen INC. | $15.57 | 2019 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lawrence Morris listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.